<DOC>
	<DOCNO>NCT01581970</DOCNO>
	<brief_summary>This feasibility study ass effectiveness cetuximab administer low dose oral cyclophosphamide . Patients metastatic squamous cell cancer head neck progress first line chemotherapy cetuximab contain regimen treat standard care weekly cetuximab twice daily low dose oral cyclophosphamide 12 week .</brief_summary>
	<brief_title>Potentiation Cetuximab Tregs Depletion With CSA Advanced Head &amp; Neck Cancer</brief_title>
	<detailed_description>In study , patient head neck squamous cell carcinoma ( HNSCC ) give low-dose cyclophosphamide combination standard care cetuximab . Tumor biopsy collect six week treatment measurement tumor infiltration effector cell , include CD8+ T cell , natural killer ( NK ) cell , monocyte . In addition , proportion Tregs effector cell measure peripheral blood time point .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically document squamous cell carcinoma head neck ( irrespective site primary nasopharyngeal , oral cavity , oropharyngeal , laryngeal unknown primary ) metastatic/incurable progress first line chemotherapy regimen . Progression measurable disease within last 6 week base Response Evaluation Criteria Solid Tumors ( RECIST ) criteria If patient receive prior treatment antiepidermal growth factor receptor ( EGFR ) therapy part definitive therapy concurrent radiation , time last cetuximab exposure must &gt; 180 day . Must least 30 day prior treatment recover reversible effect previous anticancer treatment Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 Adequate bone marrow , renal hepatic function within 14 day study enrollment define : Bone marrow : White blood cell ( WBC ) &gt; 3,000/uL ; absolute neutrophil count &gt; 1,500/uL ; platelet &gt; 100,000/uL Renal : creatinine ≤ 2.5 time institutional upper limit normal ( ULN ) Hepatic : total bilirubin &lt; 1.5 X institutional ULN ; aspartate aminotransferase/alanine aminotransferase ( AST [ SGOT ] ALT [ SGPT ] ) &lt; 2.5 X institutional ULN Albumin &gt; 3.0 gm/dL Women childbearing potential fertile men must willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study 60 day last dose study drug . Voluntary write consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care Pregnant lactating female child bear potential must negative pregnancy test within 14 day study enrollment cyclophosphamide Pregnancy Category D History another active primary invasive cancer within previous 2 year , exclude nonmelanoma skin cancer The patient receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy ( RT ) , chemoembolization , target therapy . Patients receive palliative radiation therapy bony metastasis prior first dose study medication eligible . Chronic steroid dependence Known HIVpositive patient acquired/inherited immunodeficiency hepatitis B , hepatitis C , connective tissue disease , clinical diagnosis , ongoing intercurrent illness Investigator 's opinion preclude subject participation History gastrointestinal disease cause malabsorption obstruction , limit Crohn 's disease , celiac sprue , tropical sprue , bacterial overgrowth/blind loop syndrome , gastric bypass surgery , stricture , adhesion , achalasia , bowel obstruction , extensive small bowel resection Inability take medication mouth History allergic reaction attribute compound similar chemical biologic composition Active autoimmune disease , chronic inflammatory condition , condition require concurrent use systemic immunosuppressant steroid . Mildintermittent asthma require occasional betaagonist inhaler use mild localized eczema exclude . Previous allotransplant kind</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>metastatic squamous cell cancer</keyword>
</DOC>